

Supplementary Table S1. Summary distributions of the hPG, ANXA2 and CD163/HLA-DR values in primary tumors (T), lymph node metastases (LN), patients' non-tumoral gastric mucosa (non-tumoral) and gastric mucosa of healthy controls (healthy)

	Min.	1 Q	Median	Mean	3 Q	Max.
hPG (healthy)	35	90.75	101	104.86	117	160
hPG (non-tumoral)	8	41	67	71.32	95	157
hPG (T)	0	29	64	65.43	88.25	159
hPG (LN)	0	21	57	59.51	95.5	166
ANXA2 (healthy)	5	16.25	25.5	33.55	37.25	107
ANXA2 (non-tumoral)	2	22.5	55	55.29	82	166
ANXA2 (T)	0	43	72.5	92.03	121.25	242
ANXA2 (LN)	0	50.5	94	105	161.5	285
CD163/HLA-DR (healthy)	0.116	0.374	0.688	0.642	0.898	1.055
CD163/HLA-DR (non-tumoral)	0.195	0.557	0.764	0.880	1.034	3.310
CD163/HLA-DR (T)	0.074	0.734	1.184	1.625	1.764	6.952
CD163/HLA-DR (LN)	0.150	0.704	1.167	1.335	1.720	4.267

hPG, progastrin; ANXA2, annexin A2; HLA-DR, human leukocyte antigen-DR.